Method: Plasma samples were collected from children (n = 62) enrolled in the Probiotic and Peanut Oral Immunotherapy (PPOIT) randomised placebo-controlled trial at baseline, immediately after completing 18 months of treatment, 3 months post-treatment and 4 years post-treatment. Peanut component (Arah 1, 2, 3) sIgE and sIgG4 were measured by ImmunoCAP. Two-tailed t-tests on log-transformed values were used for point-in-time between-group comparisons and generalised estimating equations (GEE) were used to compare longitudinal trends.
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Results: PPOIT was associated with changes in Arah 1, 2, 3 sIgE and sIG4 over time. sIgE decreased with treatment (age-and sex-adjusted GEE; Arah 1 P = 0.003, Arah 2 P < 0.001, Arah3 P = 0.040) and remained reduced 4 years post-treatment. At 4 years post-treatment, sIgE levels were significantly lower in PPOIT-treated subjects as compared to controls (Arah1 P = 0.017, Arah2 P = 0.008, Arah3 P = 0.042). sIgG4 increased by end-of-treatment (PPOIT v.s. Placebo; Arah1 P = 0.022, Arah2 P < 0.001, Arah3 P ≤ 0.001) but decreased thereafter returning towards baseline by 4 years post-treatment (PPOIT v.s. Placebo; Arah1 P = 0.549, Arah2 P = 0.034, Arah3 P = 0.234). At 4 years post-treatment, 8-week challenge-proven SU was associated with significantly lower sIgE levels compared with no SU (Arah1 P < 0.001, Arah2 P < 0.001, Arah3 P = 0.004); in contrast, peanut component sIgG4 levels were similar between SU and no SU participants (Arah1 p = 0.015, Arah2 P = 0.832, Arah3 P = 0.870).
Conclusion: PPOIT induces changes in sIgE and sIgG4 antibody responses to peanut components which may mediate clinical effects. Long-lasting SU is associated with persistently reduced peanut component sIgE at 4 years. In contrast, sIgG4 only increased transiently while treatment was administered, falling back towards baseline once treatment ceased. Mycoprotein ('Quorn') is a food produced from the mould, Fusarium venenatum and is an ingredient used in vegetarian foods as a meat substitute. Mycoprotein shares multiple common allergenic determinants with environmental moulds including Aspergillus fumigatus, Cladosporium herbarum and Alternaria alternata.
This case report describes a severe hypotensive anaphylaxis in a 17-yearold girl immediately after eating food containing mycoprotein -'vegetarian fajitas'. She required treatment with a fluid bolus, inhaled Ventolin, intramuscular Adrenaline and an Adrenaline infusion and intravenous steroids. Skin prick testing was subsequently strongly positive to mycoprotein. Our patient also had a history of previous allergic reactions to some mushrooms, perennial rhinitis with positive skin prick testing to Alternaria mould and pollens, asthma which was controlled with a combined preventer and mild eczema.
Reports suggest that patients sensitised to environmental mould may be at risk of a severe allergic reaction, even after their first ingestion of mycoprotein. The consumption of products containing edible fungi or food ingredients derived from fungal fermentation continues to increase and patients with significant sensitisation to mould should be made aware of the risk of an allergic reaction. Consideration should be given to labelling these foods with 'caution in individuals with mould allergy'. Results: 168 subjects were identified. The median age at time of diagnosis was 9 months (IQR = 6-15). 49% were male. 42% had comorbid atopy and 19% had existing IgE food allergy.
P42 CLINICAL FEATURES OF PAEDIATRIC PATIENTS WITH FOOD PROTEIN-INDUCED ENTEROCOLITIS SYNDROME FROM A LARGE TERTIARY CENTRE COHORT
These 168 children had 329 FPIES triggers in total. The most common were rice (44%), cow's milk (30%), soy (13%), eggs (11%) and fish (11%). 35% had multiple food triggers.
The median age at first episode was 5 months, with median delay to diagnosis being 3 months. 181 acute episodes in 108 patients required ED presentation. Overall, 64% of infants were taken to ED on at least one occasion because of FPIES.
Of the ED presentations (n = 181), the predominant symptoms were vomiting (100%), pallor (77%), floppiness (77%) and lethargy (75%). 62% of episodes presented with all four symptoms. 42% required intravenous fluid resuscitation.
In episodes where white cell (n = 60) and neutrophil counts (n = 56) were measured, 33% and 45% were elevated respectively. In episodes with recorded sodium (n = 49) and potassium levels (n = 47), 96% were normal, whereas for bicarbonate levels (n = 44), 65% were low. C-reactive protein (n = 24) was elevated (>5 mg/L) in 29% of episodes.
Conclusions:
Characteristic clinical features of FPIES were described in our cohort. Rice was the most common FPIES trigger. ED presentations were frequent and common abnormalities in routine laboratory investigations during acute episodes included low bicarbonate and elevated neutrophil count. Background: Infants with food sensitisation on skin prick testing (SPT) may either be food allergic or sensitised tolerant on subsequent oral exposure. It has been proposed that there are pathogenic versus benign patterns of aeroallergen sensitisation in early life, with pathogenic sensitisation having a substantially stronger relationship with risk of subsequent asthma.
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We hypothesise that food allergy in early life would be more strongly associated with subsequent doctor-diagnosed asthma than food sensitised tolerance.
Methods:
The Barwon Infant Study is a birth cohort study (n = 1074) assembled using an unselected antenatal sampling frame. At the 12-month review, SPT was performed against cow's milk, egg, peanut, cashew and sesame. Those with a positive result or history suggestive of food allergy were offered an in-hospital food challenge. At the 4-year review, doctordiagnosed asthma was assessed based on questionnaire. Odds ratios (OR) were adjusted for sex, family history of asthma, maternal smoking during pregnancy, pet ownership during pregnancy, presence of older siblings and any eczema by 12-month review.
Results: At 1 year, 11.4% (93/818) of children were SPT positive to 1 or more foods. On food challenge, 7.5% (61/818) were allergic and 3.3% (27/818) were tolerant. 17.0% (136/802) participants who have completed the 4-year review to date have doctor-diagnosed asthma. Food allergy at 1 year was strongly associated with doctor-diagnosed asthma at age 4 years (adjusted OR 4.3, CI 2.0-9.1, P < 0.01) whereas food sensitised tolerance was not (OR 0.7, CI 0.1-3.1, P = 0.61).
Conclusion: This is the first study to investigate whether the relationship between early food sensitisation and subsequent asthma varies between the allergic and sensitised tolerant groups. Our findings support the hypothesis that food allergy predicts subsequent asthma whereas food sensitised tolerance does not. Further comparison of these early food sensitisation 
